In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci

International Journal of Antimicrobial Agents

Volumn 29, Issue 2, 2007, Pages 191-196

  Garrison, Mark W ^a   Nuemiller, Joshua J ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

MRSA; Pharmacodynamics; Quinolone resistant S. pneumoniae; Tigecycline; VRE

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; METICILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OFLOXACIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANCE;

EID: 33846034519     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.08.048     Document Type: Article

References (20)

1. Karchmer A.W. Increased antibiotic resistance in respiratory tract pathogens: PROTECT US-and update. Clin Infect Dis 39 Suppl 3 (2004) S142-S150
2. Kuehnert M.J., Hill H.A., Kupronis B.A., et al. Methicillin-resistant Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 11 (2005) 868-872
3. Fridkin S.K., Edwards J.R., Courval J.M., et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 US adult intensive care units. Ann Intern Med 135 (2001) 175-183
4. Goldstein E.J.C., and Garabedian-Ruffalo S.M. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 35 (2002) 1505-1511
5. Styers D., Sheehan D.J., Hogan P., et al. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 5 (2006) 2-10
6. Wilcox M.H. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 6 (2005) 2315-2326
7. Cottagnoud P., Pfister M., Acosta F., et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 48 (2004) 3928-3933
8. Garrison M.W., Nuemiller J.J., and Setter S.M. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin Ther 27 (2005) 12-22
9. Garrison M.W., Schimmels J.A., and Madaras-Kelly K.J. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV. Diagn Microbiol Infect Dis 47 (2003) 587-593
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Fifteenth Informational Supplement. M100-S15. Wayne, PA, USA: CLSI; 2005.
11. Tygacil Product Insert. Wyeth Pharmceuticals Inc. Philadelphia, PA, 2005.
12. Chaplin-Robertson K., and Edberg S.C. Measurements of antibiotics in human body fluids: techniques and significance. In: Lorian V. (Ed). Antibiotics in Laboratory Medicine. 3rd edn. (1991), Williams and Wilkins, Baltimore, MD 313
13. Bouchillon S.K., Hoban D.J., Johnson B.M., et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 52 (2005) 173-179
14. Cosgrove S.E., Carroll K.C., and Perl T.M. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 39 (2004) 539-545
15. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR 53 (2004) 322-323
16. Fridkin S.K., Lawton R., Edwards J.R., et al. Monitoring antimicrobial use and resistance: comparison with national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 8 (2002) 702-707
17. Hoban D.J., Bouchillon S.K., Johnson B.M., et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52 (2005) 215-227
18. Peterson P.J., Jacobus N.V., Weiss W.J., et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43 (1999) 738-744
19. vanOgtrop M.L., Andes D., Stamstad T.J., et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 44 (2000) 943-949
20. Meagher A.K., Ambrose P.G., Grasela T.H., et al. Pharmacokinetic and pharmacodynamic profile for tigecycline a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 52 (2005) 165-171